Degradation of the Alzheimer's amyloid beta peptide by endothelin converting enzyme |
| |
Authors: | C B Eckman E A Eckman M L Watson |
| |
Institution: | Mayo Clinic, Jacksonville, FL, USA |
| |
Abstract: | The deposition of β-amyloid (Aβ) peptides in the brain is an early and invariant feature of all forms of Alzheimer's disease (AD). As such, a major focus of AD research has been the elucidation of the mechanisms responsible for the generation of Aβ. As with any peptide, however, the degree of Aβ accumulation is dependent not only on its production, but also on the mechanisms responsible for its removal. In cell-based and in vitro assays we have identified endothelin-converting enzymes (ECEs) as novel Aβ-degrading enzymes that appear to cleave predominately in an intracellular compartment. Overexpression of ECE-1 in cells that lack endogenous ECE activity reduces Aβ accumulation by up to 90%, and this effect is completely reversed by treatment of the cells with phosphoramidon. Additionally, we have shown that recombinant soluble ECE-1 is capable of hydrolyzing synthetic Aβ40 and Aβ42 in vitro at multiple sites, with a favorable kinetic profile. While several enzymes have been identified that can degrade Aβ in vitro , only neprilysin has thus far been reported to influence Aβ accumulation in the brains of knock-out mice. To examine the physiological role of ECE activity on Aβ accumulation in the brain we compared the amount of Aβ in wild-type and ECE-2 null mice. A significant elevation in both Aβ40 and Aβ42 was observed in the ECE-2 null animals compared to their wild-type littermates. These data provide direct evidence of a physiological role for this enzyme in limiting Aβ accumulation in the brain. Acknowledgements: Supported by Smith Fellowships to C.E. and E.E., a Bursak Fellowship to E.E., and by the Mayo Foundation for Medical Education and Research. |
| |
Keywords: | |
|
|